The CPM #28 confined several known diagnostic and prognostic biomarkers of endometrial cancer, such as the mismatch repair mutation, and the overexpression of MLH1, MSH2, MSH6, and PMS2. In addition, this module included the overexpression and mutation of PTEN and TP53, which significantly contribute to the diagnosis of endometrial cancer (Crosbie et al., 2022). Here, PMS2 is linked to endometrial cancer.